Form 4: Arcutis Biotherapeutics Director Patrick J. Heron Reports Stock Purchase

Director Patrick J. Heron reports the acquisition of 21,052 shares of Arcutis Biotherapeutics, Inc. common stock at $9.50 per share on March 4, 2024.

Summary

• On March 4, 2024, Patrick J. Heron, a director of Arcutis Biotherapeutics, Inc., acquired 21,052 shares of common stock at a price of $9.50 per share.
• Following the transaction, Heron beneficially owns 8,785,284 shares indirectly through Frazier Life Sciences VIII, L.P., FHM Life Sciences VIII, L.L.C., and The Heron Living Trust 11/30/2004.
• Heron also directly owns 8,687 shares, which includes 4,375 Restricted Stock Units (RSUs).

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of a stock purchase by a director. While insider buying can be seen as a positive signal, it's a single transaction and doesn't provide definitive insight into the company's overall health.

Positives

• The director's purchase of shares may signal confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders (officers, directors, or those holding more than 10% of a company's shares) buy or sell stock in their own companies. These filings are closely watched by investors as they can provide insights into management's view of the company's prospects.

Stakeholder Impact

• The stock purchase by a director could positively influence shareholder sentiment.

Key Dates